Plain-English translation of NCT07201558 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new injectable medication called in adults with rheumatoid arthritis or systemic lupus erythematosus (lupus). Researchers want to understand how safe the medication is, how your body processes it, and how it affects your disease. The study will enroll about 48 participants and test different doses to find the safest and most effective approach.
Many people with rheumatoid arthritis or lupus don't respond well enough to current treatments, or they can't tolerate them. This study is exploring whether this new medication could offer another option for people whose disease hasn't been controlled with existing therapies.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication under your skin at different visit appointments. The study has three parts with different dosing schedules—some participants get one injection, others get two or three over time. You'll have blood tests and check-ins with the research team to monitor how you're doing, watch for any side effects, and measure how the medication affects your disease.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
United States